Market Overview:
The global insulin active pharmaceutical ingredient market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about diabetes and its treatment, and technological advancements in insulin delivery devices. Based on type, the global insulin active pharmaceutical ingredient market is segmented into chemical synthetics and animal extracts. The chemical synthetics segment is further sub-segmented into human recombinant DNA (rDNA) insulins and analogues thereof. The animal extracts segment is further sub-segmented into porcine pancreatic extract (PPE), bovine pancreatic extract (BPE), and others including equine pancreatic extract (EPE) etc. Based on application, the global insulin active pharmaceutical ingredient market is divided into animal Insulin, regular human Insulin, analogue human Insulin, and others including premixes & blends etc.
Product Definition:
Insulin active pharmaceutical ingredient is a hormone that helps the body use glucose for energy. It is used to treat diabetes and low blood sugar.
Chemical Synthetics:
Chemical Synthetics is a group of chemicals that are manufactured in laboratories using conventional chemical synthesis methods. Chemical Synthetic products are used as intermediates or additives in the production of Active Pharmaceutical Ingredients (APIs). The growth factor for this market is increasing demand from pharmaceutical and biotechnology companies for advanced technologies to produce complex molecule structures with desired properties such as high efficacy and safety.
Animal Extracts:
Animal extracts and its usage in insulin active pharmaceutical ingredient market is a new emerging trend in the global healthcare industry. The demand for animal extract-based drugs has been on a rise since the past few years, owing to their high efficacy as compared to synthetic ingredients.
The increasing use of herbal medicines.
Application Insights:
The global insulin active pharmaceutical ingredient market is segmented by application into animal insulin, regular human insulin, and insulin analogue. The animal insulins segment held the largest share in 2017 due to the growing demand for pork and beef products globally. Moreover, increasing consumption of milk and dairy products along with a rise in fitness consciousness among adults is expected to drive this segment over the forecast period.
The regular human insulins segment is anticipated to witness significant growth during the forecast period on account of high product usage rates coupled with rising incidences of diabetes across all age groups globally. Furthermore, an increase in healthcare awareness has resulted in a rise in demand for new drugs that are more effective than existing options available currently. This factor will further boost industry growth over the coming years as well owing to increased usage rates of new drugs coupled with fewer side effects compared to older counterparts which have been around for many years now (but were not approved by FDA).
Regional Analysis:
North America dominated the global insulin active pharmaceutical ingredient market in 2017. The presence of a large number of manufacturers coupled with high R&D expenditure and technological advancements are some factors responsible for its dominance. Moreover, the region is expected to witness growth in future due to rising diabetic population and increasing healthcare spending by government & private sectors.
The European market was valued at USD X million in 2017 owing to presence of developed economies such as Germany, U.K.
Growth Factors:
- Increasing prevalence of diabetes: The number of people with diabetes is increasing at an alarming rate. This will drive the demand for insulin and other insulin active pharmaceutical ingredients.
- Growing awareness about diabetes and its treatment: There is a growing awareness about diabetes and its treatment options among people all over the world. This will help to drive the demand for insulin and other insulin active pharmaceutical ingredients.
- Technological advancements in Insulin delivery devices: There have been significant advancements in Insulin delivery devices in recent years, which has helped to make their use more convenient and comfortable for patients. This will help to boost the demand for insulin active pharmaceutical ingredients market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Insulin Active Pharmaceutical Ingredient Market Research Report
By Type
Chemical Synthetics, Animal Extracts
By Application
Animal Insulin, Regular Human Insulin, Insulin Analogue
By Companies
Novo Nordisk, Eli Lilly, Tong Hua Dong Bao Group, Wanbang Biopharmaceuticals, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Insulin Active Pharmaceutical Ingredient Market Report Segments:
The global Insulin Active Pharmaceutical Ingredient market is segmented on the basis of:
Types
Chemical Synthetics, Animal Extracts
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Animal Insulin, Regular Human Insulin, Insulin Analogue
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Eli Lilly
- Tong Hua Dong Bao Group
- Wanbang Biopharmaceuticals
- ...
Highlights of The Insulin Active Pharmaceutical Ingredient Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemical Synthetics
- Animal Extracts
- By Application:
- Animal Insulin
- Regular Human Insulin
- Insulin Analogue
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Insulin Active Pharmaceutical Ingredient Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Insulin Active Pharmaceutical Ingredient is a term used to describe a type of drug that contains insulin. Insulin is an important hormone that helps control blood sugar levels in people with diabetes.
Some of the key players operating in the insulin active pharmaceutical ingredient market are Novo Nordisk, Eli Lilly, Tong Hua Dong Bao Group, Wanbang Biopharmaceuticals.
The insulin active pharmaceutical ingredient market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Insulin Active Pharmaceutical Ingredient Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Insulin Active Pharmaceutical Ingredient Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Insulin Active Pharmaceutical Ingredient Market - Supply Chain
4.5. Global Insulin Active Pharmaceutical Ingredient Market Forecast
4.5.1. Insulin Active Pharmaceutical Ingredient Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Insulin Active Pharmaceutical Ingredient Market Size (000 Units) and Y-o-Y Growth
4.5.3. Insulin Active Pharmaceutical Ingredient Market Absolute $ Opportunity
5. Global Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Type
5.3.1. Chemical Synthetics
5.3.2. Animal Extracts
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Application
6.3.1. Animal Insulin
6.3.2. Regular Human Insulin
6.3.3. Insulin Analogue
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Insulin Active Pharmaceutical Ingredient Demand Share Forecast, 2019-2029
9. North America Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Application
9.4.1. Animal Insulin
9.4.2. Regular Human Insulin
9.4.3. Insulin Analogue
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Type
9.7.1. Chemical Synthetics
9.7.2. Animal Extracts
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Insulin Active Pharmaceutical Ingredient Demand Share Forecast, 2019-2029
10. Latin America Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Application
10.4.1. Animal Insulin
10.4.2. Regular Human Insulin
10.4.3. Insulin Analogue
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Type
10.7.1. Chemical Synthetics
10.7.2. Animal Extracts
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Insulin Active Pharmaceutical Ingredient Demand Share Forecast, 2019-2029
11. Europe Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Application
11.4.1. Animal Insulin
11.4.2. Regular Human Insulin
11.4.3. Insulin Analogue
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Insulin Active Pharmaceutical Ingredient Market Size and VolumeForecast by Type
11.7.1. Chemical Synthetics
11.7.2. Animal Extracts
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Insulin Active Pharmaceutical Ingredient Demand Share, 2019-2029
12. Asia Pacific Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Application
12.4.1. Animal Insulin
12.4.2. Regular Human Insulin
12.4.3. Insulin Analogue
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Type
12.7.1. Chemical Synthetics
12.7.2. Animal Extracts
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Insulin Active Pharmaceutical Ingredient Demand Share, 2019-2029
13. Middle East & Africa Insulin Active Pharmaceutical Ingredient Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Application
13.4.1. Animal Insulin
13.4.2. Regular Human Insulin
13.4.3. Insulin Analogue
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Insulin Active Pharmaceutical Ingredient Market Size and Volume Forecast by Type
13.7.1. Chemical Synthetics
13.7.2. Animal Extracts
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Insulin Active Pharmaceutical Ingredient Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Insulin Active Pharmaceutical Ingredient Market: Market Share Analysis
14.2. Insulin Active Pharmaceutical Ingredient Distributors and Customers
14.3. Insulin Active Pharmaceutical Ingredient Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Tong Hua Dong Bao Group
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Wanbang Biopharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ...
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
